2 news items
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
TPST
9 May 24
. These data further support the clinical benefit observed in the TPST-1120 Phase 1 data presented in an oral presentation at ASCO 2022
Tempest Announces Publication Of Data From Phase 1 Trial Of TPST-1120 In Patients With Advanced Solid Tumors In Journal Of Cancer Research Communications
TPST
4 Apr 24
and predominantly low-grade toxicity. Notwithstanding the late-line stage of these patients and difficult to treat tumor types, clinical benefit was observed
- Prev
- 1
- Next